1. Home
  2. KSPI vs GMAB Comparison

KSPI vs GMAB Comparison

Compare KSPI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KSPI

Joint Stock Company Kaspi.kz

HOLD

Current Price

$89.76

Market Cap

16.4B

Sector

N/A

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$25.69

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSPI
GMAB
Founded
2008
1999
Country
Kazakhstan
Denmark
Employees
N/A
3088
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4B
16.2B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
KSPI
GMAB
Price
$89.76
$25.69
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
$104.33
$39.56
AVG Volume (30 Days)
535.8K
1.8M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
8.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.90
$17.85
Revenue Next Year
$16.80
$16.04
P/E Ratio
$7.12
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$68.59
$20.23
52 Week High
$99.11
$35.43

Technical Indicators

Market Signals
Indicator
KSPI
GMAB
Relative Strength Index (RSI) 62.42 39.44
Support Level $71.17 $25.34
Resistance Level $93.59 $29.64
Average True Range (ATR) 3.02 0.71
MACD -0.11 -0.08
Stochastic Oscillator 88.11 10.88

Price Performance

Historical Comparison
KSPI
GMAB

About KSPI Joint Stock Company Kaspi.kz

Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform, which derives maximum revenue, connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: